AMCP Partnership Forum: Principles for Sound Pharmacy and Therapeutics (P&T) Committee Practices: What's Next?

It has been nearly 20 years since the Academy of Managed Care Pharmacy (AMCP) and other stakeholders adopted the Principles for a Sound Formulary System. Since that time, best practices for pharmacy and therapeutics (P&T) committees have matured throughout the health care system. On March 28, 20...

Full description

Saved in:
Bibliographic Details
Published inJournal of managed care & specialty pharmacy Vol. 26; no. 1; pp. 48 - 53
Format Journal Article
LanguageEnglish
Published United States Academy of Managed Care Pharmacy 01.01.2020
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:It has been nearly 20 years since the Academy of Managed Care Pharmacy (AMCP) and other stakeholders adopted the Principles for a Sound Formulary System. Since that time, best practices for pharmacy and therapeutics (P&T) committees have matured throughout the health care system. On March 28, 2019, AMCP convened a group of thought leaders representing clinicians, academia, patient advocacy, payer organizations, and the pharmaceutical industry to consider P&T committee best practices in today's evolving health care system. Specifically, the group provided perspectives on (a) P&T committee composition and relevant stakeholders, (b) evaluation of emerging evidence for formulary decisions and recommendations around training of P&T committee members, and (c) characteristics and best practices of successful committees. DISCLOSURES: This AMCP Partnership Forum and the development of the proceedings document were supported by Amgen, Genentech, Merck, National Pharmaceutical Council, Novo Nordisk, Pharmaceutical Research and Manufacturers of America, Precision for Value, and Takeda. This proceedings document presents common themes and comments from individuals participating in the forum and is not necessarily endorsed by all participants nor should it be construed to reflect group consensus. Eric Jen, PharmD, and Cynthia Reilly, MS, BSPharm, declare no conflicts of interest, real or apparent, with any product or service mentioned in this article. Jen is an employee of Precision for Value, a sponsor of the Partnership Forum. Development of these proceedings was done as an in-kind sponsorship. Reilly is an employee of AMCP.
Bibliography:This AMCP Partnership Forum and the development of the proceedings document were supported by Amgen, Genentech, Merck, National Pharmaceutical Council, Novo Nordisk, Pharmaceutical Research and Manufacturers of America, Precision for Value, and Takeda. This proceedings document presents common themes and comments from individuals participating in the forum and is not necessarily endorsed by all participants nor should it be construed to reflect group consensus.
Eric Jen, PharmD, and Cynthia Reilly, MS, BSPharm, declare no conflicts of interest, real or apparent, with any product or service mentioned in this article. Jen is an employee of Precision for Value, a sponsor of the Partnership Forum. Development of these proceedings was done as an in-kind sponsorship. Reilly is an employee of AMCP.
ISSN:2376-0540
2376-1032
DOI:10.18553/jmcp.2020.26.1.48